John (Jack) C Reidling

Picture of John  (Jack) C Reidling
Project Scientist, Institute for Memory Impairments and Neurological Disorders (UCI MIND)
Ph.D.
Phone: (949) 824-5692
Email: jreidlin@uci.edu
University of California, Irvine
Lab 4100 Gross Hall
Office 4107 Gross Hall
Mail Code: 4545
Irvine, CA 92697
Research Interests
Neurological disorders, memory impairment, Huntington's disease.
Academic Distinctions
Individual National Research Service Award (NRSA) NIH-NIDDK, Bethesda, MD (2003-2006)
Mentored Research Scientist Development Award (K-award) NIH-NIDDK, Bethesda, MD (2006-2011)
Appointments
1998- 2000, Postdoctoral Fellow: University of California Santa Cruz, Department of Biology, Santa Cruz, CA, Supervisor: Barry Bowman PhD. The work focused on the structure and function of the vacuolar ATPase (V-ATPase) in Neurospora crassa.
2000-2003, Postdoctoral Fellow: University of California Irvine/ Long Beach VA Medical Center, Department of Medicine, Long Beach, CA, Supervisor: Hamid Said PhD. Uptake and regulation of the B vitamins.
Research Abstract
Huntington’s disease (HD) is a devastating degenerative brain disease with a 1 in 10,000 prevalence that inevitably leads to death. Because HD is genetically dominant, the disease has a 50% chance of being inherited by the children of patients. Symptoms of the disease include uncontrolled movements, difficulties in carrying out daily tasks or continuing employment, and severe psychiatric manifestations including depression. Current treatments only address some symptoms and do not change the course of the disease, therefore a completely unmet medical need exists. Human stem cells offer a possible long-term treatment approach that could relieve the tremendous suffering experienced by patients and their families. Because HD is entirely genetic and the mutation known, a diagnosis can be made with certainty and clinical applications of stem cells may provide insights into treating brain diseases that are not caused by a single, known mutation. The ability to differentiate stem cells into neuronal populations offers a powerful and sustainable treatment opportunity. We have established a multidisciplinary team of investigators and consultants to integrate basic and translational research with the goal of generating a lead developmental candidate having disease modifying activity with sufficient promise to initiate Investigational New Drug (IND) enabling activities for HD clinical trials.
Publications
Isoform-dependent lysosomal degradation and internalization of apolipoprotein E requires autophagy proteins.
Fote GM, Geller NR, Efstathiou NE, Hendricks N, Vavvas DG, Reidling JC, Thompson LM, Steffan JS.
J Cell Sci. 2022 Jan 15;135(2):jcs258687.
Huntington's disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization.
Sanchez II, Nguyen TB, England WE, Lim RG, Vu AQ, Miramontes R, Byrne LM, Markmiller S, Lau AL, Orellana I, Curtis MA, Faull RLM, Yeo GW, Fowler CD, Reidling JC, Wild EJ, Spitale RC, Thompson LM.
J Clin Invest. 2021 Jun 15;131(12):e140723.
PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease.
Morozko EL, Smith-Geater C, Monteys AM, Pradhan S, Lim RG, Langfelder P, Kachemov M, Kulkarni JA, Zaifman J, Hill A, Stocksdale JT, Cullis PR, Wu J, Ochaba J, Miramontes R, Chakraborty A, Hazra TK, Lau A, St-Cyr S, Orellana I, Kopan L, Wang KQ, Yeung S, Leavitt BR, Reidling JC, Yang XW, Steffan JS, Davidson BL, Sarkar PS, Thompson LM.
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):e2021836118.
Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ, Reidling JC, Lim RG, Adam M, Wu J, Wassie B, Stocksdale JT, Casale MS, Fraenkel E, Thompson LM.
Hum Mol Genet. 2020 Jan 15;29(2):202-215.
Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.
Crapser JD, Ochaba J, Soni N, Reidling JC, Thompson LM, Green KN.
Brain. 2020 Jan 1;143(1):266-288.
Morozko EL, Ochaba J, Hernandez SJ, Lau A, Sanchez I, Orellana I, Kopan L, Crapser J, Duong JH, Overman J, Yeung S, Steffan JS, Reidling J, Thompson LM. Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
J Huntingtons Dis. 2018;7(4):321-335.
Holley SM, Kamdjou T, Reidling JC, Fury B, Coleal-Bergum D, Bauer G, Thompson LM, Levine MS, Cepeda C. Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.
CNS Neurosci Ther. 2018 Apr;24(4):329-342
Reidling JC, Relaño-Ginés A, Holley SM, Ochaba J, Moore C, Fury B, Lau A, Tran AH, Yeung S, Salamati D, Zhu C, Hatami A, Cepeda C, Barry JA, Kamdjou T, King A, Coleal-Bergum D, Franich NR, LaFerla FM, Steffan JS, Blurton-Jones M, Meshul CK, Bauer G, Levine MS, Chesselet MF, Thompson LM. Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice.
Stem Cell Reports. 2018 Jan 9;10(1):58-72.
HD iPSC Consortium. Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice.
Nat Neurosci. 2017 May;20(5):648-660.
Ochaba J, Monteys AM, O'Rourke JG, Reidling JC, Steffan JS, Davidson BL, Thompson LM. PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.
Neuron. 2016 May 4;90(3):507-20.
1. Hanna, M, Y. Zhang, JC Reidling, M. Thomas and J. Jou. 1993. Synthesis and characterization of a new photocrosslinking CTP analog and its use in labeling E. coli and T7 polymerases. Nucleic Acids Research, 1993, Vol. 21, no. 9 2073-2079
2. Kroiher, M., JC Reidling and R. Steele. A gene whose major transcript encodes only the substrate binding domain of a protein-tyrosine kinase. Gene, 2000, Vol. 241, 317-324
3. Reidling, JC. and R. Steele. Sweet Tooth, A novel receptor protein-tyrosine kinase with C-type lectin-like extracellular domains. Journal of Biol. Chem. 2000 Vol. 275, No.14 10323-10330
4. Reidling, JC., Subramanian, V., Dudeja, P., and H. Said. Expression and promoter analysis of SLC19A2 in the human intestine. Biochem. Biophys. Acta 1561, 2002, 180-187
5. Said, H., Reidling, JC., and A. Ortiz, Cellular and molecular aspects of thiamin uptake by human liver cells: studies with cultured HepG2 cells. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):106-12.
6. Reidling JC, Said HM. In vitro and in vivo characterization of the minimal promoter region of the human thiamin transporter SLC19A2. Am J Physiol Cell Physiol. 2003 Sep;285(3):C633-41.
7. Reidling JC, Said HM. Adaptive Regulation of Intestinal Thiamin Uptake: Molecular Mechanism using Wild-type & Transgenic Mice carrying hTHTR-1 & 2 Promoters. Am J Physiol GI 2004 (in press)
8. Reidling JC, Nabokina SM, Balamuragon K, and Said HM. Ontogenic Regulation of Intestinal Thiamin Uptake: Molecular Mechanisms in Wild-Type & Transgenic Mice Carrying the Human Thiamin Transporters-1 and 2 Promoters. J Physiol 2005 (submitted)
9. Nabokina SM, Reidling JC, Said HM. Differentiation-dependent up-regulation of intestinal thiamin uptake: cellular and molecular mechanisms. J Biol Chem. 2005 Sep 23;280(38):32676-82.
10. Reidling JC, Nabokina SM, Balamurugan K, Said HM. Developmental maturation of intestinal and renal thiamin uptake: studies in wild-type and transgenic mice carrying human THTR-1 and 2 promoters. J Cell Physiol. 2006 Feb;206(2):371-7.
11. Chavez C, Bowman EJ, Reidling JC, Haw KH, Bowman BJ. Analysis of strains with mutations in six genes encoding subunits of the V-ATPase: eukaryotes differ in the composition of the V0 sector of the enzyme. J Biol Chem. 2006 Sep 15;281(37):27052-62.
12. Reidling JC, Nabokina SM, Said HM. Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: A study of the hSMVT system. Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G275-81.
13. Reidling JC, Said HM. Regulation of the human biotin transporter hSMVT promoter by KLF-4 and AP-2: confirmation of promoter activity in vivo. Am J Physiol Cell Physiol. 2007 Apr;292(4):C1305-12.
14. Subramanian VS, Marchant JS, Reidling JC, Said HM. N-Glycosylation is required for Na+-dependent vitamin C transporter functionality. Biochem Biophys Res Commun. 2008 Sep 12;374(1):123-7.
15. Subramanian VS, Reidling JC, Said HM. Differentiation-dependent regulation of the intestinal folate uptake process: studies with Caco-2 cells and native mouse intestine. Am J Physiol Cell Physiol. 2008 Sep;295(3):C828-35.
16. Reidling JC, Subramanian VS, Dahhan T, Sadat M, Said HM. Mechanisms and Regulation of Vitamin C Uptake: Studies of the hSVCT Systems in Human Liver Epithelial Cells. Am J Physiol Gastrointest Liver Physiol. 2008 Dec;295(6):G1217-27.
17. Reidling JC, Lambrecht N, Kassir M, Said HM. Impaired Intestinal Vitamin B(1) (Thiamin) Uptake in Thiamin Transporter-2-Deficient Mice. Gastroenterology. 2010 May;138(5):1802-9.
18. Reidling JC, Rubin SA. Promoter Analysis of the Human Ascorbic Acid Transporters SVCT1 & 2: Mechanisms of Adaptive Regulation in Liver Epithelial Cells. J Nutr Biochem. 2011 Apr;22(4):344-50.
19. Mattis VB, Wakeman DR, Tom C, Dodiya HB, Yeung SY, Tran AH, Bernau K, Ornelas L, Sahabian A, Reidling J, Sareen D, Thompson LM, Kordower JH, Svendsen CN. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Exp Neurol. 2014 Apr;254:90-8.
20. Miller S, Hill Della Puppa G, Reidling J, Marcora E, Thompson LM, Treanor J. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease. J Huntingtons Dis. 2014;3(4):333-41.
Grants
CIRM Preclinical Development Award (Leslie Thompson)
Last updated
11/03/2022